Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HXN5003 in Healthy Participants and Patients With Moderate-to-Severe Atopic Dermatitis
NCT07801612Phase 1Not yet recruiting
- Sponsor
- Helixon
- Start
- Sep 2026
- Primary completion
- Oct 2027
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of HXN5003 in atopic dermatitis (AD) (4 arms), sponsored by Helixon. Primary endpoints: Adverse Events in Part A and Adverse Events in Part B. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
HXN5003
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT07801612.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07801612.